Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23259058 | 0.93 | KDR (0.53) | KDRTRPV1PDGFRBFLT3BRAF | |
| SCHEMBL18037963 | 0.92 | KDR (0.56) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL23258570 | 0.91 | KDR (0.55) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL23258939 | 0.91 | KDR (0.50) | KDRTRPV1PDGFRBFLT3BRAF | |
| SCHEMBL18037966 | 0.90 | KDR (0.51) | KDRTRPV1PDGFRBFLT3BRAF | |
| SCHEMBL23258590 | 0.89 | KDR (0.53) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL18038053 | 0.89 | KDR (0.53) | KDRTRPV1PDGFRBFLT3BRAF | |
| SCHEMBL23258943 | 0.89 | KDR (0.53) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL23258194 | 0.89 | KDR (0.53) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL23259063 | 0.89 | ALDH1A1 (0.47) | KDRFLT3BRAFALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDR 1402/4885TRPV1 4556/4885PDGFRB 1067/4885 |
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KDR 1402/4885TRPV1 4556/4885PDGFRB 1067/4885 |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDR 1402/4885TRPV1 4556/4885PDGFRB 1067/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDR 1402/4885TRPV1 4556/4885PDGFRB 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.